[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600316":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":32,"studyPopulation":24,"armGroups":33,"interventions":40,"overallOfficials":46,"centralContacts":50,"locations":60,"responsibleParty":80,"collaborators":24,"id":82,"slug":24,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":24,"enrollmentInfo":91,"targetDuration":24,"studyType":94,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":63,"whyStopped":24,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Asociación para Evitar la Ceguera en México","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"BCVA (Best corrected visual acuity)","Ability to discriminate fine details at a standard distance, assessed by reading letters on an ETDRS chart.","From the first recruitment evaluation to the last one at 3 months post-surgery",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"Postoperative anatomical changes of the macula using optical coherence tomography: Central macular thickness (µm)","Central macular thickness measured in microns (µm)","From enrollment to the end of follow-up at the third month.",{"measure":19,"description":20,"timeFrame":17},"Postoperative anatomical changes of the macula using optical coherence tomography: Inner nuclear layer thickness (µm)","Inner nuclear layer thickness measured in microns (µm)",{"measure":22,"description":23,"timeFrame":17},"Postoperative anatomical changes of the macula using optical coherence tomography: Ellipsoid zone disruption","Presence or absence of disruption of the Ellipsoid layer",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":28,"primaryPurpose":29,"observationalModel":24,"timePerspective":24,"maskingInfo":30},"NA","SINGLE_GROUP","Prospective, Longitudinal, Experimental, Descriptive Cohort Study.","TREATMENT",{"masking":31,"maskingDescription":24,"whoMasked":24},"NONE","The evolution of visual acuity will be analyzed using the ETDRS letter scale. At the same time, anatomical and microvascular changes will be evaluated using optical coherence tomography (OCT) and optical coherence tomography angiography (OCT-A) to evaluate their impact on visual recovery. This technique is expected to minimize persistent distortion, promote restoration of retinal perfusion, mitigate postoperative ischemia, and improve macular structural stability, potentially leading to more significant functional recovery. It is designed as a prospective longitudinal pilot study; The research will be carried out in the Retina Department of the Association to Prevent Blindness in Mexico (APEC), focusing on patients over 18 years of age with a diagnosis of advanced MRD and eligible for vitreoretinal surgery.",[34],{"label":35,"type":36,"description":37,"interventionNames":38},"Patient protocol","EXPERIMENTAL","Patients over 18 years of age, with a clinical diagnosis of Epiretinal Membrane grade 3 and 4 according to Optical Coherence Tomography, who attend the Retina service.",[39],"Procedure: Pars plana vitrectomy with epiretinal membrane peeling and controlled macular detachment",[41],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":24},"PROCEDURE","Pars plana vitrectomy with epiretinal membrane peeling and controlled macular detachment","Currently, vitrectomy with epiretinal membrane peeling is the standard procedure; however, its ability to improve visual acuity in these patients remains limited. In this context, controlled macular detachment is emerging as a surgical alternative that could optimize the anatomical and functional restoration of the retina.",[35],[47],{"name":48,"affiliation":5,"role":49},"Raul Velez, MD","PRINCIPAL_INVESTIGATOR",[51,56],{"name":52,"role":53,"phone":54,"phoneExt":24,"email":55},"Raúl Velez Montoya, MD","CONTACT","(52) 55 5436 7335","rvelezmx@yahoo.com",{"name":57,"role":53,"phone":58,"phoneExt":24,"email":59},"Oriana Gomez Erazo, MD","57 3205605466","orianagomezerazo@gmail.com",[61],{"facility":62,"status":63,"city":64,"state":24,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Hospital Asociación Para Evitar la Ceguera en México I.A.P.","RECRUITING","Mexico City","04030","Mexico","MX",{"type":69,"coordinates":70},"Point",[71,72],-99.12766,19.42847,{"lat":72,"lon":71},[75,79],{"name":76,"role":53,"phone":77,"phoneExt":78,"email":59},"Oriana Gomez, MD","52 5510841400","1302",{"name":48,"role":49,"phone":24,"phoneExt":24,"email":24},{"type":81,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100600316",false,"NCT07095907","Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment","Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment: Pilot Study.","DMER25","Inclusion Criteria:\n\n* Patients over 18 years of age.\n* Patients with a confirmed diagnosis of ERM grade III or IV by Optical Coherence Tomography who present visual disturbances such as metamorphopsia or visual impairment (measured in letters on the ETDRS scale) but who do not reflect end-stage visual impairment.\n* Patients suitable for vitreoretinal surgical procedures, with no uncontrolled medical comorbidities that contraindicate surgery.\n* Patients who understand the objectives and risks of the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with a confirmed diagnosis of grade III or IV ERM by Optical Coherence Tomography who do not have the ability to improve their visual acuity.\n* Patients diagnosed with ocular pathologies that significantly affect their visual acuity, such as moderate or advanced glaucoma, non-glaucomatous optic neuropathies, or optic media opacities such as leukomas, significant corneal edema, or other maculopathies such as macular atrophy or macular ischemia.","ALL","18 Years",{"count":92,"type":93},36,"ESTIMATED","INTERVENTIONAL",[26],"This study aims to evaluate postsurgical functional changes in patients with advanced epiretinal membrane (ERM) (stages 3 and 4) by integrating a controlled macular detachment with a balanced salt solution to the conventional ERM peeling technique.",[98],"Epiretinal Membrane Surgery",[100,101,102],"Epiretinal membrane","Epiretinal membrane surgery","Macular detachment","2025-07-29",{"date":105,"type":106},"2025-07-31","ACTUAL",{"date":108,"type":106},"2025-06-10",{"date":110,"type":93},"2026-01-26",{"name":5,"class":6},1]